Shenzhen Fosun Kairos Biotechnology Co., Ltd.

Clinical trials sponsored by Shenzhen Fosun Kairos Biotechnology Co., Ltd., explained in plain language.

Now part of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 600196 SSE

A subsidiary of Fosun Pharma focused on biologics and biosimilars.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Automated CAR-T therapy shows promise for Tough-to-Treat lymphoma Results expected Nov 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1 Not yet recruiting 2

Automated CAR-T therapy shows promise for Tough-to-Treat lymphoma

Disease control Recruiting now

This early-phase trial is testing a CAR-T cell therapy made using an automated process for people with relapsed or refractory large B-cell lymphoma. The study will enroll 12 adults whose cancer has not responded to or returned after first-line treatment. Researchers will measure …

Early phase 1 • Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 13:03 UTC

Shenzhen Fosun Kairos Biotechnology Co., Ltd.

Upcoming readouts

Automated CAR-T therapy shows promise for Tough-to-Treat lymphoma